These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 30797495)

  • 21. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
    Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
    Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of a robust radiomic biomarker of progression-free survival in advanced non-small cell lung cancer patients treated with first-line immunotherapy.
    Singh A; Horng H; Roshkovan L; Weeks JK; Hershman M; Noël P; Luna JM; Cohen EA; Pantalone L; Shinohara RT; Bauml JM; Thompson JC; Aggarwal C; Carpenter EL; Katz SI; Kontos D
    Sci Rep; 2022 Jun; 12(1):9993. PubMed ID: 35705618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Computed tomography-based radiomics for the differential diagnosis of pneumonitis in stage IV non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Tohidinezhad F; Bontempi D; Zhang Z; Dingemans AM; Aerts J; Bootsma G; Vansteenkiste J; Hashemi S; Smit E; Gietema H; Aerts HJ; Dekker A; Hendriks LEL; Traverso A; De Ruysscher D
    Eur J Cancer; 2023 Apr; 183():142-151. PubMed ID: 36857819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Applicability of a prognostic CT-based radiomic signature model trained on stage I-III non-small cell lung cancer in stage IV non-small cell lung cancer.
    de Jong EEC; van Elmpt W; Rizzo S; Colarieti A; Spitaleri G; Leijenaar RTH; Jochems A; Hendriks LEL; Troost EGC; Reymen B; Dingemans AC; Lambin P
    Lung Cancer; 2018 Oct; 124():6-11. PubMed ID: 30268481
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Radiomics-Clinical Model Predicts Overall Survival of Non-Small Cell Lung Cancer Patients Treated with Immunotherapy: A Multicenter Study.
    Yolchuyeva S; Giacomazzi E; Tonneau M; Ebrahimpour L; Lamaze FC; Orain M; Coulombe F; Malo J; Belkaid W; Routy B; Joubert P; Manem VSK
    Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer.
    Ohri N; Piperdi B; Garg MK; Bodner WR; Gucalp R; Perez-Soler R; Keller SM; Guha C
    Lung Cancer; 2015 Jan; 87(1):23-7. PubMed ID: 25468149
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy.
    Fucà G; Galli G; Poggi M; Lo Russo G; Proto C; Imbimbo M; Vitali M; Ganzinelli M; Lanti C; Molino G; Stangoni F; Zilembo N; de Braud F; Garassino MC; Signorelli D
    Target Oncol; 2018 Dec; 13(6):795-800. PubMed ID: 30306460
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radiomic phenotype features predict pathological response in non-small cell lung cancer.
    Coroller TP; Agrawal V; Narayan V; Hou Y; Grossmann P; Lee SW; Mak RH; Aerts HJ
    Radiother Oncol; 2016 Jun; 119(3):480-6. PubMed ID: 27085484
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications.
    Ricciuti B; Dahlberg SE; Adeni A; Sholl LM; Nishino M; Awad MM
    J Clin Oncol; 2019 Aug; 37(22):1927-1934. PubMed ID: 31206316
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systematic review of radiomic biomarkers for predicting immune checkpoint inhibitor treatment outcomes.
    Zhang C; de A F Fonseca L; Shi Z; Zhu C; Dekker A; Bermejo I; Wee L
    Methods; 2021 Apr; 188():61-72. PubMed ID: 33271285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer.
    Zhao S; Zhang Z; Zhang Y; Hong S; Zhou T; Yang Y; Fang W; Zhao H; Zhang L
    Int J Cancer; 2019 Jun; 144(11):2854-2866. PubMed ID: 30430561
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted Therapy and Immunotherapy in the Treatment of Non-Small Cell Lung Cancer.
    Shroff GS; de Groot PM; Papadimitrakopoulou VA; Truong MT; Carter BW
    Radiol Clin North Am; 2018 May; 56(3):485-495. PubMed ID: 29622080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune Microenvironment Differences Between Squamous and Non-squamous Non-small-cell Lung Cancer and Their Influence on the Prognosis.
    Meng X; Gao Y; Yang L; Jing H; Teng F; Huang Z; Xing L
    Clin Lung Cancer; 2019 Jan; 20(1):48-58. PubMed ID: 30341017
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer.
    Sekine K; Kanda S; Goto Y; Horinouchi H; Fujiwara Y; Yamamoto N; Motoi N; Ohe Y
    Lung Cancer; 2018 Oct; 124():179-188. PubMed ID: 30268458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Dammeijer F; Lievense LA; Veerman GD; Hoogsteden HC; Hegmans JP; Arends LR; Aerts JG
    J Clin Oncol; 2016 Sep; 34(26):3204-12. PubMed ID: 27432922
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A Single Center Analysis of Advanced Non-small Cell Lung Cancer Patients Treated with Immunotherapy in Real-world Practice].
    Liu Y; Zhang T; Gao Y; Qu Y; Lu B; Zhang H; Wang Q; Li J; Hu F; Li B
    Zhongguo Fei Ai Za Zhi; 2019 Nov; 22(11):687-695. PubMed ID: 31771737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current status and quality of radiomic studies for predicting immunotherapy response and outcome in patients with non-small cell lung cancer: a systematic review and meta-analysis.
    Chen Q; Zhang L; Mo X; You J; Chen L; Fang J; Wang F; Jin Z; Zhang B; Zhang S
    Eur J Nucl Med Mol Imaging; 2021 Dec; 49(1):345-360. PubMed ID: 34402924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.
    Yang J; Chen J; Wei J; Liu X; Cho WC
    Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preliminary Report on Computed Tomography Radiomics Features as Biomarkers to Immunotherapy Selection in Lung Adenocarcinoma Patients.
    Granata V; Fusco R; Costa M; Picone C; Cozzi D; Moroni C; La Casella GV; Montanino A; Monti R; Mazzoni F; Grassi R; Malagnino VG; Cappabianca S; Grassi R; Miele V; Petrillo A
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multi-subtype classification model for non-small cell lung cancer based on radiomics: SLS model.
    Liu J; Cui J; Liu F; Yuan Y; Guo F; Zhang G
    Med Phys; 2019 Jul; 46(7):3091-3100. PubMed ID: 31002395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.